{"id":30234,"date":"2026-07-03T01:05:00","date_gmt":"2026-07-02T23:05:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=70257b1453fdcedfcc956f643deaccd2"},"modified":"2026-07-03T01:05:00","modified_gmt":"2026-07-02T23:05:00","slug":"xeris-announces-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=30234","title":{"rendered":"Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"},"content":{"rendered":"

CHICAGO--(BUSINESS WIRE)--#GvokeHypoPen<\/a>--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris\u2019 Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris\u2019 Inducement Equity Plan.<\/p><\/a><\/a>

\nXeris\u2019 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments and are subject to the employees\u2019 continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris\u2019 Inducement Equity Plan and forms of award agreements covering the grants.<\/p>

\nAbout Xeris<\/b><\/p>

\nXeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev\u00ae, for the treatment of endogenous Cushing\u2019s syndrome; Gvoke\u00ae, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis\u00ae, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as early-stage programs leveraging Xeris\u2019 technology platforms, XeriSol\u00ae and XeriJect\u00ae, for its partners.<\/p>

\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com<\/a>, or follow us on X<\/a>, LinkedIn<\/a>, or Instagram<\/a>.<\/p> Contacts<\/b>

\nInvestor Contact<\/b>Allison Wey\nSenior Vice President, Investor Relations\nawey@xerispharma.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

CHICAGO–(BUSINESS WIRE)–#GvokeHypoPen–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, tod…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-30234","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30234"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30234\/revisions"}],"predecessor-version":[{"id":30235,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30234\/revisions\/30235"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}